Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2015-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The epidemiology of severe trauma has undergone changes in recent years due to the global aging of society, resulting in different populations with older ages and more associated comorbidities. These factors are frequently linked to the use of chronic treatments such as antiplatelet agents or anticoagulants, which could worsen traumatic hemorrhage-the leading preventable cause of death following severe trauma. Despite efforts for primary prevention, such as road safety campaigns and occupational risk prevention, the annual incidence of severe trauma cases worldwide remains high. Enhancing the management of trauma patients would significantly influence the final clinical outcomes.
Given the aforementioned, it is of vital importance to understand the local epidemiology of severe trauma for the development of clinical research. This constitutes an effective tool to investigate changes in clinical practices, improve prevention strategies, and determine the global burden of the disease.
The hypothesis of the IcuTrauma Project is to create a territorial Registry of adults with severe trauma admitted to the ICU to understand the local epidemiology in Tarragona (Spain). This initiative would facilitate new lines of clinical research aimed at improving outcomes and the quality of care for trauma patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In-Hospital Electronic Registry of Severe Trauma of the Fondazione I.R.C.C.S. Policlinico San Matteo
NCT06930820
TBI-Prognosis Multicenter Prospective Study
NCT02452541
Outcome in Traumatic Brain Injury Elderly Patients
NCT04651803
Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage
NCT01619709
Study to Improve Outcomes for Survivors of Traumatic Brain Injury in Latin America
NCT01068522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Study period: Seven-years period: Since 01 January 2015 - 31 December 2022 (The registry will be open and active recruiting after this time point).
* Sample size calculation: Not applicable. The sample size will be equal to the total number of patients consecutively admitted to the Intensive Care Unit (ICU) due to severe trauma during the study period.
* Data extraction:
Data will be extracted by twofold:
1. Hand-driven: extracted data from the medical reports by reviewing the clinical history system performed by the study investigators, who are part of the staff of the ICU involved in the care of trauma patients. This information was collected into a large-scale database and, once introduced, the data was checked and verified by two investigators (and principal investigator).
These manually extracted data included pre-hospital variables (such as the time of the injury, the mechanism of injury, first vital signs, pre-hospital procedures), in-hospital information (demographic's, primary survey of trauma in emergency department-ED, use of Extended Focused Assesment with Sonography in Trauma, complete laboratory results in ED), description of detailed anatomic injuries (Traumatic Brain Injury-TBI, thoracic trauma, abdominal trauma, Pelvic trauma, orthopedic injuries), severity scores (Acute Physiology And Chronic Health Evaluation-APACHE II, Sequential Organ Failure Assessment-SOFA score, Injury Severity Score-ISS, Abbreviated Injury Score-AIS, etc), resources during ICU admission (surgeries, transfusions, organ support, etc), complications (organ failures and nosocomial infections such as ventilator-associated pneumonia, catheter-related infection, etc), and clinical outcomes (ICU mortality, cause of death, in-hospital mortality, one-year survival, mechanical ventilation days, ICU and hospital length of stay, disability at ICU discharge and destination at discharge.
2. Automatic data: automated data collected with the Electronic Health System (Centricity Critical Care) provide solid and valid extraction of information. Automatic variables were checked and validated by the expert and specialized members of the ICU in data quality assessment and the management of data to ensure that recorded information was reliable. The accuracy, completeness and representativeness of automatic data was double checked when entered into the large-scale database for data quality by the principal investigator and a biotechnologist, who were responsible for the quality assurance plan that addressed data validation, monitoring and auditing (identifying inconsistencies, outliers or incorrect ranges for variables entered into the registry). The automated variables collected (not recorded manually) included demographic data, comorbidities and previous risk factors, dates (hospital and ICU admission, hospital and ICU discharge), laboratory tests during the first week of ICU admission, resources consumption during ICU stay, complications during ICU admission and outcomes.
* Statistical plan: descriptive and analytical statistics using binary logistic regression (for association), survival analysis with Kaplan Meier analysis and Cox regression (for clinical outcomes), nonlinear association test such as CHAID decision analysis and restricted cubic splines, and matching learning analysis (for cluster or subgroups identification). These analyzes will be carried out using SPSS v24 and R software. Missing data values of automated variables will be handled using multiple imputation. Hand-driven data had negligible missing values.
* Variable definitions (all definitions met the ATLS-Advanced Trauma Life Support criteria):
* Previous anticoagulants or antiplatelet agents: chronic use of aspirin, clopidogrel, other antiplatelet agents, acenocumarol, warfarin, new anticoagulants.
* Pre-hospital airway protection: includes supraglottic device, orotracheal intubation or surgical airway protection.
* Penetrating trauma: knifes, firearm, impalement or others.
* Flail chest: more than 3 ribs with fracture in two points.
* Lung contusion: pulmonary infiltrate or condensation on initial X-rays after trauma.
* Hemothorax type: simple (any pleural fluid detected after trauma), massive (\>1.5 Liters acute or \> 200cc/h in 2-4 hours).
* Type of pneumothorax: simple (presence of aire in pleural space), hypertensive (with hypotension and/or respiratory failure).
* Myocardial dysfunction (ventricular dysfunction detected in echocardiography or worsening of previous cardiac dysfunction).
* Abdominal injuries grade (hepatic, spleen and renal trauma): anatomical scale injury using the AAST-The American Association for the Surgery of Trauma.
* Pelvic fracture classification: Young-Burgees pelvic ring injury classification.
* Neurogenic shock: bradycardia with hypoperfusion.
* Urgent surgery: first 24 hours after trauma.
* Hemorragia shock: hypoperfusion (with or without hypotension) defined by tachicardia, coldness, peripheral vasoconstriction, need for vasopressors, altered mental status, oliguria, hyperlactatemia or base excess deficit \< - 6 due to the loss of blood after injury.
* Damage control surgery: Non-definitive surgery consisting in packing for hemorrhage control, open abdomen, intestinal contamination control.
* Massive hemorrhage: \>10 CH in the first 24 hours, life-threatening hemorrhage, or \> four blood products in the first 2 hours after admission.
* Intracranial hypertension (ICH): episode of Intracranial pressures \> 20-22 mmHg maintained for more than five minutes.
* First level of ICH measures: general measures, sedation, neuromuscular blockade, ventricular drainage, osmotherapy.
* Second level of ICH measures: decompressive craniectomy or brabiturics administration.
* Osmotherapy: administration of hypertonic saline or mannitol during admission.
* Intracranial rebleeding: increase in hematoma volume from initial tomography (CT scan).
* Organ donor: organ donation.
* ARDS (Acute respiratory distress syndrome): according the Berlin criteria.
* Protective mechanical ventilation: applying tidal volumes 6-8 ml/Kg ideal body weight.
* Free liquid CT: neither solid nor hollow viscera injury.
* Non-operative management (NOM) for abdominal trauma: solid organ injury detected in CT scan managed through conservative management (no need for surgery at least 6-8 hours).
* MNO failure: urgent laparotomy after deciding NOM.
* White laparotomy: absence of lesions observed in the laparotomy.
* Abdominal compartment syndrome: results from the progression of steady-state pressure within the abdominal cavity to a repeated pathological elevation of pressure above 20mmHg with associated organ dysfunction.
* Early MODS (Multiorgan dysfunction syndrome): dysfunction of two or more organs in the first 72 hours after trauma.
* Renal failure: according to AKIN guidelines.
* Trauma-induced Coagulopathy (TIC): prolongation of the prothrombin and activated partial thromboplastin times over 1.5 times the control values, or fibrinogen \< 150 mg/dL or thrombocytopenia \< 100.000/ml in the first 72 hours after trauma.
* Septic shock: identification of sepsis plus organ failure or tissue hypoperfusion.
* Thrombosis: any type (deep vein thrombosis, arterial, pulmonary embolism).
* Tracheostomy: percutaneous or surgical.
* Nosocomial infection: any infection diagnosed after 48 hours of ICU admission.
* VAP (Ventilator-associated pneumonia): clinical and microbiologically confirmed pneumonia in patients ventilated for at least 48 hours.
* VAT (Ventilator-associated tracheobronchitis): upper respiratory tract infection (without pneumonia) in patients ventilated for at least 48h.
* CRI (Catheter-related infection): bacteremia with positive catheter culture for the same microorganism and no other source of infection, with a minimum of 15 colony formation units in the catheter culture.
* Intra-abdominal infection: peritonitis, abscess, positive surgical fluid.
* Infection of open fractures: positive culture of the wound.
* MDR (multidrug resistant) infection: includes any bacteria resistant to at least three antibiotic families.
* Limitation of life support: withholding or withdrawal.
* Causes of death: hemorrhagic shock, early MODS, late MODS, septic shock, refractory ICH (without response to applied measures), others.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Trauma admitted outside the ICU
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari Joan XXIII de Tarragona.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gerard Moreno
PhD, Staff of Intensive Care Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerard Moreno, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitari Joan XXIII
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Joan XXIII
Tarragona, Catalonia/Tarragona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICUTRAUMA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.